Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
equine botulinum neurotoxin G immune fab2
- Development stage
- Unknown
- Lead developer
- Cangene
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Equine Botulinum Neurotoxin G Immune FAB2 is a mixture of antibody fragments (primarily F(ab')2 and Fab) derived from the plasma of horses immunized with botulinum toxin serotype G. It is used for the treatment of symptomatic or suspected exposure to botulinum neurotoxin type G as part of a heptavalent antitoxin product that covers all seven known serotypes (A-G). The mechanism of action involves binding and neutralizing circulating unbound botulinum toxin molecules before they can enter nerve terminals and exert their toxic effects. This product is administered intravenously in emergency settings for both adult and pediatric patients exposed to any covered serotype[1][2][5][8].
- Brand names
- BAT
- Other names
- equine botulinum neurotoxin G immune fab2botulism antitoxin heptavalent (A, B, C, D, E, F, G) - (equine)HBAT
02
Targets
BoNT/G (Botulinum neurotoxin type G)
Beyond the preview
Go deeper on equine botulinum neurotoxin G immune fab2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on equine botulinum neurotoxin G immune fab2.